Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
13
POAI Quote, Financials, Valuation and Earnings
Last price:
$5.50
Seasonality move
:
-11.59%
Day range:
$5.31 - $6.00
52-week range:
$4.76 - $45.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
16.89x
P/B ratio:
4.71x
Volume:
55.4K
Avg. volume:
30.8K
1-year change:
-55.19%
Market cap:
$4.2M
Revenue:
$1.6M
EPS (TTM):
-$115.91
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Predictive Oncology, Inc. has 716.7% upside to fair value with a price target of -- per share.
POAI vs. S&P 500
-
Over the past 5 trading days, Predictive Oncology, Inc. has underperformed the S&P 500 by -7.87% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Predictive Oncology, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Predictive Oncology, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Predictive Oncology, Inc. reported revenues of $3.6K.
Earnings Growth
-
Predictive Oncology, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Predictive Oncology, Inc. reported earnings per share of -$107.25.
Enterprise value:
5.9M
EV / Invested capital:
-0.08x
Price / LTM sales:
16.89x
EV / EBIT:
--
EV / Revenue:
8.12x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.67x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$140.6K
Return On Assets:
-1686.19%
Net Income Margin (TTM):
-11536.93%
Return On Equity:
-1065.31%
Return On Invested Capital:
-282.32%
Operating Margin:
-91108.33%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.8M | $395.6K | $728.2K | $3.9K | $3.6K | |
| Gross Profit | $445.5K | -$396.2K | -$140.6K | -$165.5K | -$179.3K | |
| Operating Income | -$14.4M | -$11.2M | -$10.4M | -$2.2M | -$3.3M | |
| EBITDA | -$13.6M | -$10.7M | -$9.8M | -$2M | -$3.1M | |
| Diluted EPS | -$15.63 | -$44.81 | -$115.91 | -$6.17 | -$107.25 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $43M | $26.9M | $13.5M | $4.6M | $1.1M | |
| Total Assets | $51.2M | $33.2M | $18.2M | $7.5M | $3.1M | |
| Current Liabilities | $3M | $3.5M | $4.2M | $3.8M | $79.5M | |
| Total Liabilities | $3.4M | $3.6M | $6.5M | $5.5M | $80.6M | |
| Total Equity | $47.8M | $29.6M | $11.7M | $2M | -$77.4M | |
| Total Debt | $1M | $5.5K | $2.3M | $1.7M | $1.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$12.3M | -$13.9M | -$8.8M | -$3.2M | -$1.7M | |
| Cash From Investing | -$126.7K | -$216.8K | $657K | $32K | -- | |
| Cash From Financing | $236.6K | $4M | $4.4M | $888.3K | $1.3M | |
| Free Cash Flow | -$12.4M | -$13.9M | -$8.8M | -$3.2M | -$1.7M | |
POAI
Sector
Market Cap
$4.2M
$28.4M
Price % of 52-Week High
12%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-38.81%
-1.32%
1-Year Price Total Return
-55.19%
-22.19%
Beta (5-Year)
1.354
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$5.89
200-day SMA
Sell
Level
$13.75
Bollinger Bands (100)
Sell
Level
8.05 - 14.63
Chaikin Money Flow
Sell
Level
-25.9M
20-day SMA
Sell
Level
$6.14
Relative Strength Index (RSI14)
Sell
Level
32.04
ADX Line
Sell
Level
12.92
Williams %R
Buy
Level
-93.2185
50-day SMA
Sell
Level
$9.56
MACD (12, 26)
Sell
Level
-1.01
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
35.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-57.4282)
Sell
CA Score
(Annual)
Level (-5.8717)
Sell
Beneish M-Score
(Annual)
Level (-0.3529)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (12.9022)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.
Stock Forecast FAQ
In the current month, POAI has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The POAI average analyst price target in the past 3 months is --.
-
Where Will Predictive Oncology, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Predictive Oncology, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Predictive Oncology, Inc.?
Analysts are divided on their view about Predictive Oncology, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Predictive Oncology, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Predictive Oncology, Inc.'s Price Target?
The price target for Predictive Oncology, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is POAI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Predictive Oncology, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of POAI?
You can purchase shares of Predictive Oncology, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Predictive Oncology, Inc. shares.
-
What Is The Predictive Oncology, Inc. Share Price Today?
Predictive Oncology, Inc. was last trading at $5.50 per share. This represents the most recent stock quote for Predictive Oncology, Inc.. Yesterday, Predictive Oncology, Inc. closed at $5.51 per share.
-
How To Buy Predictive Oncology, Inc. Stock Online?
In order to purchase Predictive Oncology, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get POAI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
POAI
Sector
P/E ratio
--
23.66x
PEG ratio
0.00x
-0.01x
P/B ratio
4.71x
1.84x
Price / LTM sales
16.89x
1.60x
Growth Metrics
POAI
Sector
Revenue growth
-7.4%
4.85%
Earnings growth
-1637.95%
11.15%
Revenue (5-year growth)
2.84%
6.45%
Earnings forecast
--
-$0.20
Profitability
POAI
Sector
Profitability FY 2024
$635.6K
$3.6M
Return on invested capital
-282.32%
-30.98%
Return on assets
-1686.19%
-27.62%
Return on equity
-1065.31%
-36.69%
Earnings Date
Last Earnings Date
Aug
14
Next Earnings Date
Dec
5
Estimated Next Earnings Date
Mar
6
Balance Sheet
POAI
Sector
Total cash
$181.7K
$27.2M
Short term investments
--
$25.7M
Total assets
$5M
$79.9M
Long term debt
$1.1M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
